<DOC>
	<DOCNO>NCT00434447</DOCNO>
	<brief_summary>This study design monitor safety efficacy long-term treatment zoledronic acid assess incidence , renal impairment , osteonecrosis jaw ( ONJ ) , overall safety skeletal related event ( SREs ) beyond 12 month treatment</brief_summary>
	<brief_title>Long Term Efficacy Safety Zoledronic Acid Treatment Patients With Bone Metastases</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Inclusion criterion : Documented bone metastasis breast cancer , prostate cancer multiple myeloma Prior treatment zoledronic acid 12 yrs Life expectancy least 6 month Exclusion criterion : Prior treatment bisphosphonates zoledronic acid Abnormal kidney function Current previous dental problem plan dental surgery Pregnant likely become pregnant study Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Zoledronic acid</keyword>
	<keyword>Bone metastasis</keyword>
	<keyword>Skeletal Related Events ( SREs )</keyword>
	<keyword>Renal Impairment</keyword>
	<keyword>Osteonecrosis Jaw ( ONJ )</keyword>
	<keyword>Bone involvement</keyword>
	<keyword>Multiple Myeloma ( MM )</keyword>
</DOC>